Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
<p>Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.</p>
Sábháilte in:
| Príomhchruthaitheoir: | Seyed Reza Mousavi (13223324) (author) |
|---|---|
| Rannpháirtithe: | Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author) |
| Foilsithe / Cruthaithe: |
2025
|
| Ábhair: | |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
de réir: Seyed Reza Mousavi (13223324)
Foilsithe / Cruthaithe: (2025) -
Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
de réir: Seyed Reza Mousavi (13223324)
Foilsithe / Cruthaithe: (2025) -
The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
de réir: Seyed Reza Mousavi (13223324)
Foilsithe / Cruthaithe: (2025) -
Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
de réir: Seyed Reza Mousavi (13223324)
Foilsithe / Cruthaithe: (2025) -
Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
de réir: Anna Starshinova (22571846)
Foilsithe / Cruthaithe: (2025)